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Abstract 
 
ABSTRACT 
Aim of the study was to record and assess the adverse drug reactions during the 
treatment of diabetes mellitus in hospital. All the age groups and body weight groups were 
included in this study. Both male and female were included in this study. In-patients and out-
patients receiving various anti-diabetic drugs were interviewed and reported adverse drug 
reactions were recorded.  
Particularly patients taking treatment with metformin, gliclazide, insulin, pioglitazone 
and sitagliptin treated patients were assessed for adverse drug reactions. Data collected 
during the study period was documented and analysed using various statistical analysis after 
segregating age wise, body weight wise, and male and female gender wise. Finally data was 
analysed using Naranjo’s documentation system along with WHO documentation system.  
The results of the present study indicated that metformin shows diarrhea as major 
adverse reaction compared to other adverse reactions. This was followed by nausea/vomiting 
and flatulence. Other adverse reactions were abdominal discomfort, lactic acidosis, renal 
impairment and impaired hepatic functions. Gliclazide reported with parcreatitis as major 
adverse reaction followed by body weight gain, impaired hepatic functions and other minor 
adverse reactions. The first line therapy for type-1 diabetes, insulin has reported many 
adverse reactions compared to other drugs. Insulin reported hypoglycaemia as major adverse 
effect followed by weight gain and peripherial oedema as second largest adverse reactions. 
Other minor adverse reactions like hypotension, fatigure, asthenia and dyspnoea were also 
reported and recorded. Pioglitazone reported with weight gain and impaired hepatic functions 
as major adverse effect and pancreatitis, myocardial infraction were also reported. The other 
class of treatment DPP-4 inhibition sitagliptin was reported with impaired hepatic function 
Abstract 
 
and pancreatitis which contributes to 25% each and other minor adverse effects like 
hypoglycaemia, renal impairment were reported.  
These data were analysed using Naranjo’s casualty assessment along with WHO 
adverse drug reaction assessment scale. WHO casualty assessment form was in agreement 
with Naranjo’s assessment. Considering the all kind of adverse drug reactions and nature of 
severity there is an urgent need for setting up pharmacovigilance centres and recording the 
adverse reactions for cost effective and healthy India.    
 
ABBREVIATION 
ABPI  Association of the British Pharmaceutical Industry 
ACCORD Action to Control Cardiovascular Risk in Diabetes 
ACE  Angiotensin Converting Enzyme 
ADA  American Diabetes Association 
ADE  Adverse Drug Event 
ADRAC     Adverse Drug Reaction Advisory Committee 
ADRs  Adverse Drug Reactions 
ADRU        Adverse Drug Reactions Unit   
AE              Adverse Events  
BNF  British National Formulary 
CDCSO     Central Drugs Standard Control Organization 
CHD          Coronary Heart Disease 
CHF  Congestive Heart Failure 
CSM         Committee on Safety of Medicines  
CV  Cardiovascular 
DM  Diabetes mellitus 
DPP4  Dipeptidyl peptidase-4 
e.g  Example 
FDA  Food and Drug Administration 
G6PD        Glucose 6-Phosphate Dehydrogenase  
GIP  Glucose dependent Insulinotropic polypeptide 
GLP-1  Glucogan like peptide -1 
HDL  High Density Lipoprotein 
Ig E              Immunoglobulin E 
IP                 In-Patients 
MHRA        Medicines and Health-Care Products Regulatory Agency 
MI             Myocardial Infarction 
MIMS         Monthly Index of Medical Specialities 
NAT2          N-Acetyl Transference 
NGOs  Non-Governmental Organizations 
NIDDM Non-insulin dependent diabetes mellitus 
NPAC          National Pharmacovigilance Advisory Committee 
NSAIDs       Non-steroidal anti-inflammatory Drugs 
OP               Out-Patients 
PPC             Pheripheral Pharmacovigilance Centers 
PV                Pharmacovigilance 
PVD  Peripheral Cardiovascular Disease 
TGA            Therapeutic Goods Administration 
UKPDS U.K. Prospective Diabetes Study 
UMC           Upsala Monitoring Center 
WHO              World Health Organization 
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1. INTRODUCTION 
 
Adverse Drug Reaction  
An adverse drug reaction (ADR) or adverse drug event (ADE) is an expression 
that describes the unwanted, negative consequences associated with the use of given 
medications. An ADR is a particular type of adverse effect and the meaning of this 
expression differs from the meaning of "side effect", as this last expression might also imply 
that the effects can be beneficial (Nebeker et al., 2004). The study of ADRs is the concern of 
the field known as pharmacovigilance. 
The World Health Organization (WHO)  defines an adverse drug reaction  (ADR) as 
“Any response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the 
modification of physiological function” (Dogra et al., 2013). The food and Drug 
Administration (FDA) defines an ADR as “an undesirable effect, reasonably associated with 
the use of the drug that may occur as a part or may be unpredictable in its occurrence.” There 
are various mechanisms are involved in the cause of adverse drug reactions including allergy, 
nausea/vomiting etc.  
The ADR reporting system 
 The World Health Organization Collaborating Centre for International Drug 
Monitoring was established in 1971 and since that the Centre collates spontaneous ADR 
reports from participating national centers with aims to increase the early recognition of new 
and unexpected ADRs.  By combining reports from many countries from all over the world, 
very rare adverse reactions can be detected (Dogra et al., 2013, Vikas Dhikav et al., 2004). 
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There are different colour cards are used for ADR reporting. Australia follows blue card 
system and UK follows yellow card system. These reported ADRs will be analysed using 
Naranjo’s casualty assessment to decide up on the severity.  
Diabetes mellitus is the commonest endocrine disorder that affects more than 100 
million people worldwide (6% of the population) and in the next 10 years it may affect about 
five times more people that it does now (WHO/Acadia, 1992; ADA, 1997). In India, the 
prevalence rate of diabetes is estimated to be 1-5% (Patel et al., 1986; Rao et al., 1989). 
Complications are the cause of mortality and morbidity in diabetes mellitus (DM). DM alone 
ranks the top ten causes of death in Western nations, and despite important improvements in 
its clinical management to date it has not been possible to control significantly its lethal 
consequences.  
Diabetes mellitus 
 Diabetes is a metabolic disorder that is characterized by high blood glucose and either 
insufficient or ineffective insulin. This can be divided into three major subclasses i) type 1 
diabetes mellitus, ii) type 2 diabetes mellitus and iii) Gestational diabetes, normally occurs 
during pregnancy may also lead to diabetes after delivery in some cases. 
Type 1 diabetes mellitus: 
Type 1 diabetes (previously known as insulin dependent diabetes mellitus; IDDM) is 
characterized by beta cell destruction by an autoimmune process usually leading to absolute 
insulin deficiency and acute onset, usually before 25 years of age (Jennifer Mayfield, 1998). 
Symptoms of type 1 diabetes usually develop over a short period, although beta cell 
destruction can begin years earlier. Symptoms may include increased thirst and urination, 
constant hunger, weight loss, blurred vision and extreme fatigue.  
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Type 2 diabetes mellitus:  
 Type 2 diabetes mellitus (previously known as non-insulin dependent diabetes 
mellitus; NIDDM) is characterized by insulin resistance in peripheral tissue and insulin 
secretory defect of the beta cell (Jennifer Mayfield, 1998). This is the most common form of 
diabetes mellitus and is highly associated with a family history of diabetes, older age, obesity 
and lack of exercise. Defective beta cells become exhausted, further fueling the cycle of 
glucose intolerance and hyperglycemia.  The plasma insulin level in type 2 diabetes patients 
are higher than or equal to that of non diabetic control subjects (Yalow and Berson, 1960). 
This suggests that type 2 DM results from insulin resistance rather than insulin deficiency. 
However, it has become clear that both insulin resistance (Kahn, 1994) and insulin deficiency 
come in to play to cause hyperglycemia in type 2 DM patients. Insulin resistance and 
hyperinsulinemia may also be associated with hypertension and hypertriglyceridemia, 
decreased-high density lipoprotein (HDL) cholesterol and increased risk of atherosclerosis 
and cardiovascular disease (Reaven, 1988; Karam, 1992). 
Gestational diabetes  
Some women develop gestational diabetes late in pregnancy, though this form of 
diabetes usually disappears after the birth of the baby. However, women who have had 
gestational diabetes have a 20-50 % chance of developing type 2 diabetes within 5 to 10 
years. As with type 2 diabetes, gestational diabetes occurs more often in some ethnic groups 
and women with family history of diabetes. Gestational diabetes is caused by hormones of 
pregnancy or a shortage of insulin.  
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Drugs treatment for diabetes mellitus: 
Insulin:  
Insulin is the first line therapy for type-1 diabetes mellitus. Insulin is a hormone 
which helps to regulate blood sugar. There are different classification of Insulin like short 
acting, long acting, intermediate acting and rapid acting insulin. (Goodman & Gilman’s, 
2006)  
Biguanides / Metformin 
The only available diabetes medication in the biguanides class of drugs is metformin. 
Biguanides prevent the liver from producing glucose and helps to improve the body’s 
sensitivity towards insulin. Metformin is commonly used as a first line treatment for type 2 
diabetes and may occasionally be prescribed, in combination with insulin, for people with 
type 1 diabetes. Metformin was approved in 1994 (in the USA)  
Sulphonylureas 
Sulphonylureas are the class of antidiabetic drug for type 2 diabetes that tends to 
include those drugs which end in ‘ide’. The following drugs are all in the sulphonylureas 
class (branded names in brackets): Glibenclamide –also known as Glyburide (Daonil), 
Glipizide (Glucotrol), Gliquidone (Glurenorm), Glyclopyramide (Deamelin-S), Glimepiride 
(Amaryl) Gliclazide (Diamicron). 
Meglitinides / Prandial glucose regulator / Glinides 
The glinides are a class of drug which have a similar response as sulphonylureas but 
act for a shorter time. Meglitinides are prescribed to be taken by people with type 2 diabetes 
within half an hour before eating.  
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Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors, such as acarbose (marketed as Precose or Glucobay) or 
miglitol (branded as Glyset) are drugs for type 2 diabetes which slow down the digestion of 
carbohydrates in the small intestine and therefore can help to reduce after meal blood sugar 
levels. (Goodman & Gilman’s, 2006) 
Thiazolidinedione / Glitazones 
Thiazolidinediones, also known as glitazones, are a medication for type 2 diabetes 
which helps to improve insulin sensitivity and have been found to help decrease triglyceride 
levels.  However, these have recently been in public spotlight as questions over their long 
term safety. In September 2010, the most popularly prescribed drug in this class rosiglitazone 
(Avandia) was banned for use by the European medicines Agency over heart attack concerns. 
Pioglitazone works by making cells more sensitive to insulin, which is used to regulate the 
level of glucose in the body. Improving insulin sensitivity (or reducing insulin resistance) 
makes it easier for sugar (glucose) in the blood to get into the cells.  
DPP-4 inhibitors / Gliptins 
DPP-4 inhibitors, also known as gliptins, are a class of drug which help to stimulate 
the production of insulin and reduce the production of glucagon, particularly during 
digestion. DPP-4 inhibitors are usually prescribed for people with type 2 diabetes who have 
not responded well to drugs such as metformin and sulphonylureas. This drug class includes 
following medications (trade names in brackets): Sitagliptin (Januvia), Vildagliptin (Galvus), 
Saxagliptin (Onglyza), Linagliptin (Tradjenta) –approved for use in the USA. When more of 
these hormones are released blood sugar levels are reduced. It is available as 100mg tablets in 
the market. (Goodman & Gilman’s, 2006) 
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Incretin mimetics / GLP-1 analogues 
Incretin mimetics, also known as GLP-1 analogues, are an injectable treatment for type 2 
diabetes. Incretin mimetics look to mimic the effect of a group of hormones called incretins 
which increase the production of insulin and decrease the release of glucagon in a relatively 
similar way DPP-4 inhibitors. 
Pharmacovigilance 
Pharmacovigilance is an important and integral part of clinical research. Despite its 40 years 
history, pharmacovigilance remains a dynamic clinical and scientific discipline. It continues 
to play a crucial role in meeting the challenges posed by the ever increasing range and 
potency of medicines. When adverse effects and toxicity do appear especially, when 
previously unknown, it is essential that these are reported, analysed and their significance 
communicated effectively to an audience that has the knowledge to interpret the information, 
which carry an inevitable and some for all medicines there is a trade-off between the benefits 
and the potential for harm. In Indian scenario, we have national pharmacovigilance program 
and the reported adverse reactions to be recorded and reported to national pharmacovigilance 
program.  
Impact of pharmacovigilance on diabetes 
There are various class of anti-diabetic medicines are available in the market for the diabetes 
mellitus treatment. Drugs like insulin, pioglitazone, sitagliptin etc are available as anti-
diabetic drugs. These drugs are belongs to certain classification. Those chemical 
classification would have got some adverse effects and they could have been withdrawn from 
the market like rosiglitazone (thiozolidinethione derivative). From the same chemical class, 
pioglitazone is available in the market. So certain adverse effects belongs to that chemical 
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class like body weight gain, fluid retention etc can be monitored. DPP-4 inhibitors are known 
for hepatic impairment and biguanides (metformin) are known for pancreaatitis. So these 
adverse effects needs to be recorded and patients to be advised for the reported adverse effect 
before the treatment. This will help them in facing the serious adverse reactions, some are 
fatal. In the current study, I have taken pharmacovigilance program for diabetes mellitus 
treatment considering anti-diabetics like insulin, gliclazide, pioglitazone, metformin and 
sitagliptin.  
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2. LITERATURE REVIEW 
Adverse Drug Reaction  
An adverse drug reaction (ADR) or adverse drug event (ADE) is an expression 
that describes the unwanted, negative consequences associated with the use of given 
medications. An ADR is a particular type of adverse effect and the meaning of this 
expression differs from the meaning of "side effect", as this last expression might also imply 
that the effects can be beneficial (Nebeker et al., 2004). The study of ADRs is the concern of 
the field known as pharmacovigilance (PV).  
Adverse drugs reactions (ADRs), put simply, are noxious, unintended, and 
undesirable effects that occur as a result of drug treatment at doses normally used in man for 
the diagnosis, prophylaxis, and treatment.  Although there are many terms indicating the 
harmful and undesirable effects of drug treatment, the term ‘adverse drug reaction’ describes 
them best.  During the course of treatment, drugs prescribed to patients produce certain 
effects other than the desired or expected effects (Nebeker et al., 2004). 
 These cause concern both to the physician and the patient and they not only add to 
spiraling costs of medical treatments, but also cause a great deal or morbidity and mortality.  
These are generally referred to as ‘side effects’ and  the people usually attribute these 
abnormal effects to either overdose or inappropriate medications prescribed by the doctor or 
the attending specialists (Nebeker et al., 2004). The unwanted effects are categorized into 
many types such as toxic effects, side effects, adverse reactions, and adverse drug events etc. 
depending upon the taxonomic classification used. Further, the worldwide, studies have 
showed that ADRs are the major cause of morbidity and mortality. 
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Though the Indian studies in this regard are very few, the pattern of reactions seems to 
be similar.  Moreover, we have certain peculiarities of drug use such as: large number of 
patients, poor doctor-patient ratio, and self-medication, drugs of alternative systems of 
medicine, malnutrition, widespread anemia, presence of counterfeit drugs, and presence of 
the highest number of drug combinational products in the world (Vikas et al., 2004). 
 
 Therefore, incidence of the adverse drug reactions is likely to be same as that of the 
West, or more (Vikas et al., 2004).  Unfortunately, in spite of presence of five well-organized 
centers for drug monitoring in the country, the number of reports sent annually is dismal. 
This calls for the urgent need to reinforce the monitoring of adverse reactions with the help of 
public education against self-medication, inclusion of reaction monitoring, and an 
introduction to drug-safety in the curriculum of medical undergraduates, and systemic and 
periodic continuing medical education of health professionals.  This multi-pronged strategy 
can lead to reduction in the incidence of adverse drug reactions. 
Definition 
The World Health Organization (WHO)  defines an adverse drug reaction  (ADR) as 
“Any response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the 
modification of physiological function” (Dogra et al., 2013). The food and Drug 
Administration (FDA) defines an ADR as “an undesirable effect, reasonably associated with 
the use of the drug that may occur as a part or may be unpredictable in its occurrence.” On 
the other hand, adverse drug event (ADE) may be defined as an injury resulting from medical 
intervention related to a drug which appears to be a more comprehensive and clinically 
relevant description of the problem than does ADR (Dogra et al., 2013). 
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PREDISPOSING FACTORS  
 There are many factors that can predispose to the occurrence of adverse drug 
reactions in a patient who have one or more of the following predisposing factors are at high 
risk of developing ADRs.  
Polypharmacy:  
Patients with multiple drug therapy are more prone to develop an adverse drug 
reaction either due to alteration of drug effect through an interaction mechanism or by 
synergistic effect (Fulton et al., 2005).  The amount of risk associated with multiple drug 
therapy increases in direct proportion to the number of drugs administered (Dogra et al., 
2013, Classen et al., 2005). 
Age:   
Elderly and pediatric are more vulnerable to develop ADRs.  Elderly patients are 
more susceptible to ADRs to the physiological changes (pharmacokinetic and 
pharmacodynamics) which accompany aging, and also because they are often taking many 
drugs for chronic and multiple diseases. Pediatric patients may develop serious adverse drug 
reactions to some drugs since all children, especially neonates, differ in their drug handling 
capacity compared to adults.  An example of such s serious reaction is the gray baby 
syndrome with chloramphenicol (Dogra et al., 2013). 
Drugs characteristics:  
Some drugs are highly toxic in nature and patient who are treated with these agents 
are at an increased risk of ADRs. For example, nausea and vomiting is a common adverse 
drug reaction seen in patients with antinuclear drugs.  Also, patients who are treated with 
drugs, which have a narrow therapeutic index such as digoxin and gentamycin, are more 
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susceptible to develop ADRs, as a slight increase in the serum drug concentration of these 
drugs may result in drug toxicity (Dogra et al., 2013). 
Gender:   
It has been reported that women are more susceptible to develop an ADR, for 
unknown reasons. Cholramphenicol induced aplastic anemia and phenylbutazone induced 
agranulocytosis is twice and thrice as common, respectively in women patients (Dogra et al., 
2013). 
Race and genetics:   
It is evident that ADRs are more common in genetically predisposed individual.  For 
example, patients who are genetically deficient of glucose 6-phosphate dehydrogenase 
(G6PD) enzyme are at higher risk of developing hemolysis due to primaquine as compared to 
genetically eficient.  Race as well as genetic polymorphism may account for alterations in 
handling of drugs and their end organ effects (Dogra et al., 2013). 
CAUSES AND CLASSIFICATION OF ADVERSE DRUG REACTIONS 
Basically two different mechanisms are involved and is responsible for the developing 
ADRs which are as follows: 
The first Type A is an extension of the normal pharmacological effect of a drug or its 
metabolites. The second Type B is unrelated to the normal pharmacogical effect of the drug. 
Type A reactions are usually predictable, dose or clearance dependent, and most often 
preventable whereas type B reactions are idiosyncratic, often allergic or immunogenic in 
nature, neither dose nor clearance dependent, and rarely avoidable (Dogra et al., 2013). 
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Further type B reaction can be divided by the type of immune mediator involved, i.e., IgM, or 
T cell. Another type of ADR results from the long term use of a drug, with the cumulative 
dose, being the causative factor and such reaction would be cardio toxic which may occurs 
after prolonged cumulative dosing with Doxorubicin. Delayed effect of drugs or their 
metabolites, i.e., teratogrnicity, car cinogenicity, also may be considered to be mechanism of 
adverse drug reactions. 
The Gell and Coombs classification system describes the predominant immune 
mechanisms that lead to clinical symptoms of drug hypersensitivity. This classification 
system includes type I reactions (IgE-mediated); n type II reactions (Cytotoxic); Type III 
reactions (immune complex); and Type IV reactions (delayed, cell-mediated). However, 
some drug hypersensitivity reactions are difficult to classify because of a lack of evidence 
supporting a predominant immunologic mechanism. These include certain cutaneous drug 
reactions (i.e., maculopapular rashes, erthroderma, exfoliative dermatitis, and fixed drug 
reactions) and specific drug hypersensitivity syndromes. Unpredictable nonimmune drug 
reactions can be classified as pseudoallergic, idiosyncratic or intolerance. Pseudoallergic 
reactions are the result of direct mast cell activation and degranulation by drugs such as 
opiates, vancomycin (Vancocin), and radio contrast media. These reactions may be clinically 
indistinguishable from Type I hypersensitivity, but do not involve drug-specific IgE. 
Idiosyncratic reactions are qualitatively aberrant that cannot be explained by know the 
pharmacologic action of the drug and occur only in a small percent of the population. A 
classic example of an idiosyncratic reaction is drug included hemolysis in persons with 
glucose-6- phosphate dehydrogenase (G6PD) deficiency. Drug intolerance is defined as a 
lower threshold to the normal pharmacologic action of a drug, such as tinnitus after a single 
average dose of aspirin (Dogra et al., 2013). 
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 The ADRs are occasionally classified as acute, sub-acute, or latent according to their 
onset or severity. Acute events are those observed within 60 minutes after the administration 
of a medication and include anaphylactic shock, severe bronchconstruction, and nausea or 
vomiting. Sub-acute reactions occur within 1 to 24 hours and include maculopapular rash, 
serum sickness, allergic vacuities and antibiotic-associated diarrhea or colitis. Whereas. The 
latent reactions require 2 or more days to become apparent and include eczematous eruptions, 
organ toxicity, and tardive dyskinesia (Dogra et al., 2013).. Further, ADRs can also be 
classified as mild, moderate, or severe and mild reactions may include dysgyesia associated 
with clarithromycin, are bothersome but may not require a change in therapy, additional 
treatment, or continued hospitalization. Reactions that are disabling or life-threatening, or 
those that considerably prolong hospitalization, are classified as severe. 
 
 The classification of Rawlins and Thompson is perhaps the most widely used to 
describe adverse drug reactions. Adverse reactions are categorized as Type A or B. Type 
reactions are those that extend directly from a drug pharmacological effect. They are often 
predictable and dose-dependent. Type A reactions also include adverse effects resulting from 
drug overdose and drug-drug interactions. Sedation caused by an antihistamine or 
hypotension caused by a beta-adrenergic antagonist is considered Type A reactions. Type B 
reactions are idiosyncratic or immunologic reactions that are often rare and unpredictable. 
Examples of Type B reactions include aplastic anemia by chloramphenicol or rash included 
by betalactam antibiotics.  Albeit not universally accepted, other authors have extended this 
classification system to include Types C, D and E reactions to describe chemical, delayed, 
and end-of-treatment reactions, respectively.  Will and Brown have proposed, on the basis of 
mechanism, eight categories of ADR. (Dogra et al., 2013). 
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Type A (Augmented):  
Type-A reactions are dose related actions of a medicine upon the human body, which 
could have been predicated based upon knowledge of this mode of action and pharmacology 
of a drug or excipient. These reactions are the most common type of adverse reactions and 
improve if medicine is withdrawn (Vikas Dhikav et al., 2004). Predictable by the 
pharmacological mechanisms, e.g., hypotension by beta-blockers, hypoglycemia caused by 
insulin or oral hypoglycemic, or NSAID included gastric ulcers 
Type B (Bugs/ Bizarre):  
 These reactions rely upon promoting the growth the certain micro-organism. Type B 
reactions are pharmacologically predictable events and improve if medicine is withdrawn. 
Rare, idiosyncratic, genetically determined, unpredictable, mechanisms are unknown, serious, 
can be final; unrelated to the dose, e.g., hepatitis caused by halothane, a plastic anaemias 
caused by chloramphenicol, neuroleptic   malignant  syndrome caused by some anesthetics 
and anti-psychotic (Vikas Dhikav et al., 2004). 
Type C (Chemical): 
 A number of adverse reactions depend upon the chemical nature of a drug or 
excipient rather than pharmacological properties. The severity of this reaction is more a 
function of concentration of the offending substance than dose. 
Type D (Delivery/Delayed): 
 A variety of adverse reactions occur as a specific consequence of the method of drug 
delivery. This reaction does not depend upon the chemical or pharmacological properties but 
occurs because of the physical nature of the formulation and/ or the method of administration. 
Type-d are delayed occurrence of ADRs, even after the cessation of treatment, e.g., corneal 
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opacities after thioridazine, ophthalmopathy after chloroquine, or pulmonary/peritoneal 
fibrosis by methylerzide. (Vikas Dhikav et al., 2004). 
Type E (Exit/End of lose): 
 Type E reactions are known as withdrawal reactions and are a manifestation of 
physical dependence. It is possible for them to occur only after the administration of the 
medicine has ceased or the does is suddenly reduced and the reaction is linked more to 
duration of administration than dose. Withdrawal reactions occurs typically with the 
depressant drugs, e.g., hypertension and restless in opiate abstainer, seizures on alcohol or 
benzodiazepines withdrawal; first dose hypotension caused by alpha-blockers (Prazosin) or 
ACE inhibitors (Vikas Dhikav et al., 2004). 
Type F (Familial/Failure of Therapy): 
Certain adverse reactions occur only in susceptible individuals with genetically 
determined, inherited, metabolic disorders .These reactions must not be confused with those 
that occur because of the normal variation in ability to metabolize, a drug among population. 
Results from the ineffective treatment (previously excluded from analysis according to WHO 
definition), e.g., accelerated hypertension because of inefficient control. If adverse drug 
reactions are considered as any other medical illness and approached in the same way, then 
many questions would appear like: with timely invention, many of the adverse drug reactions 
can be prevented. Focus of the studies in the pharmacovigilance has now shifted from 
knowing the incidence, patterns, severity and predictability to prevention. Many programmes 
and approaches are being tired in the western countries to know what can be done to prevent 
the adverse drug reactions. This has made the study of pharmacovigilance more relevant than 
ever before (Dogra et al., 2013, Vikas Dhikav et al., 2004). 
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Type G (Genotoxicity):  
A number of drugs can produce genetic damages in humans and notably, some are 
potentially carcinogenic or genotoxic. Some, but not all, teratogenic agents damage genetic 
material within the fetus (Vikas Dhikav et al., 2004). 
Type H (Hypersensitivity): 
Type H reactions are side effects caused by allergy or hypersensitivity. They are 
probably the most common adverse reactions after Type a reactions. These are many different 
types, but all involve activation of an immune response. They are not pharmacologically 
predictable and dose dependent. Occurs as a result of continuous drug use and may be 
irreversible, unexpected, unpredictable, e.g., tardive dyskinesias by antipsychotic, dementia 
by anticholinergic medications (Vikas Dhikav et al., 2004). 
Type U (Unclassified): 
 Some ADRs have a mechanism that is not understood and these must remain 
unclassified until more is known about them. This may necessitate the introduction of new 
adverse reaction categories in future (Vikas Dhikav et al., 2004). 
 
MECHANISM OF ADVERSE DRUG REACTION 
Mechanisms of Type ‘A’ Adverse Drug Reactions 
 A drug suspected to have caused an adverse drug reaction in one patient may not 
necessarily cause the similar adverse reaction in another patient.  This is due to inter-
individual variability, which may predispose an individual to an ADR.  Any type A reaction, 
which occurs in an individual, may be attributed to any one or more of the following 
mechanisms (Dogra et al., 2013). 
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Pharmaceutical causes 
 The possible pharmaceutical causes which might be attributed to occurrence of a type- 
A adverse drug reaction include changes in the drug quantity present in a particular product, 
and also changes in its drug release properties.  For example, there are several reported 
reactions of gastrointestinal bleeding and hemorrhage due to a rate-controlled preparation of 
indomethacin.  This may be due to irritant effects of high concentrations of indomethacin on 
a localized area of gastrointestinal mucosa.  Another example is the corrosive effects on the 
esophagus caused by certain doxycycline salts.  By changing to another salt, the risk may be 
reduced dramatically. To avoid such reactions, the drug regulatory authorities have laid down 
stringent requirements for marked drug products. 
Pharmacokinetic causes 
 Alterations in the absorption, distribution, metabolism and elimination of drugs may 
alter drug effects by changing the concentration of drug present at the site of action.  The 
change in the drug effect due to alterations in pharmacokinetic parameters may be 
experienced as either therapeutic failure or toxicity (Dogra et al., 2013). 
Absorption:   
Alterations in the rate and extent of drug absorption may result in adverse drug 
effects.  The plasma concentration of a drug is partly determined by the rate at which the drug 
is absorbed after ingestion or injection.  The plasma concentration of an orally administered 
drug in turn depends greatly on the gastric emptying rate.  Similarly, the extent of drug 
absorption (the total amount of drug reaching the general circulation) also plays an important 
role in altered response.  Following oral administration, many factors may influence the 
extent of drug absorption including drug formulation, gastrointestinal motility, and first pass 
metabolism, concomitant administration of other drugs and the absorptive capacity of 
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gastrointestinal mucosa.  Any alteration in the rate or extent of drug absorption may result in 
either therapeutic failure or toxicity. 
Distribution:   
There are several factors, which determine the extent of distribution of a drug 
including regional blood flow, membrane and protein/tissue binding.  Changes in drug 
distribution may predispose to adverse drug reactions, although the clinical significance of 
such mechanisms is yet to be proved. 
Metabolism:   
The drug handling capacity of an individual can greatly affect the drug effect.  In an 
individual who has a reduced metabolic rate, accumulation of drug in the  body may be 
higher, leading to increased risk of adverse drug reactions (especially type A reactions), while 
therapeutic failure may occur in an individual who has an enhanced metabolic rate.  These 
changes are due to inter-individual variations in drug metabolizing capacity, which in turn is 
greatly influenced by genetic, environmental and other factors.  For example ‘slow 
acetylators’ are highly prone to develop type A reaction to drugs which are metabolized by 
acetylation, such as isoniazid, dapsone, hydralazine and procainamide.  Also differences in 
the rate of oxidation by cytochrome P450 system are of clinical importance (Dogra et al., 
2013).  
Elimination:   
The major routes of excretion for many drugs are the liver and kidneys by which 
metabolites are being formed and excreted.  One of the most important causes of type A 
adverse drug reaction is a change in the drug elimination rate. Drug accumulation due to 
reduced elimination may predispose to adverse drug reactions as a result of increased drug 
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concentration in plasma and tissue.  Conversely, reduced concentration of drug in plasma and 
tissue due to enhanced drug elimination may lead to therapeutic failure. 
Pharmacodynamic causes: 
 Increased sensitivity of target tissues or organs may predispose a person to adverse 
drug reactions.  Although the reasons why different individuals react differently to drugs are 
still not clear, evidence is accumulating to suggest that target tissue or organ sensitivity is 
influenced by the drug receptors themselves, by homeostatic mechanisms or  by disease it-
self  (Dogra et al., 2013). 
Drug receptors:   
Most drugs elicit their response by combining with receptors and these receptors are 
basically either protein molecules or enzymes.  The amount and sensitivity of receptors of 
one individual may differ from another individual.  Some individuals may have fewer 
specific drug receptors while others may have a higher number of less active receptors.  This 
intervariability between different individuals can greatly affect the drug effect, when the drug 
acts through these specific receptors. 
Homeostatic mechanisms:   
Many physiological factors   may determine the extent of a drug’s effect in an 
individual as drug effects occur within the environment of the body’s physiological 
mechanisms.  For example, intravenous atropine produces a variable increase in heart rate 
and some individuals develop tachycardia of 160 beats per minute at a dose which is almost 
ineffective in others.  The magnitude of the observed effect is dependant on the balance 
between parasympathetic and sympathetic cardiac tone, which appears to be under genetic 
control (Dogra et al., 2013). 
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Disease:    
The pharmacological effects of a drug which are not apparent in a healthy individual 
may be unmasked by intercurrent diseases.  An example is an asthmatic patient who develops 
bronchoconstriction while taking non-selective beta-blockers such as propranolol. 
Mechanisms of Type ‘B’ Adverse Reaction 
 The type ‘B’ reactions are aberrant in terms of the normal pharmacology of the drug 
and they are a heterogeneous group of unpredictable adverse effects.  By definition, type ‘B’ 
reactions are unrelated to the pharmacology.  The major sources for type ‘B’ reactions 
include decomposition of the active ingredients, the effects of non-drug excipients (additives, 
preservatives, colouring and solubilising agent) and synthetic by-products of active 
constituents.  In the majority of cases the use of decomposed drug products may result in 
therapeutic failure and even in some instances, though not all, the decomposed product may 
be highly toxic and lethal.   Deaths have been reported due to decomposition of paraldehyde 
to acetaldehyde and its subsequent oxidation to acetic acid.  There is a clear recognition of 
adverse drug reactions caused by excipients.  Many additives including propylene glycol and 
carboxymethylcellulose may cause hypersensitivity reactions.  The eosinophiliamyalgia 
syndrome associated with L-trytophan may be related to the use of preparations containing a 
contaminant, although a genetic factor may also be involved (Dogra et al., 2013). 
Impact of ADRs on Health-Care Costs 
 In a recent estimate, the annual national cost of drug-related morbidity and mortality 
was placed at $ 76.6 billon, with the majority related to hospital admissions associated with 
drug therapy or the absence of appropriate drug therapy.  Two recent studies have specifically 
estimated the costs of adverse drug events (James et al., 2004).  Classen et al found that for 
patients with adverse drug events occurring during hospitalization, the hospitalization was 
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longer by 3.23 days and the mean cost of hospitalization was greater by $4655 than that for 
patients who did not experience an adverse drug event.  In a more detailed analysis it was 
determined that the extra length of hospital stay attributable to an adverse drug event was 
1.74 days and the excess cost attributable to an adverse drug event was 1.74 days and the 
excess cost attributable to and adverse drug event was $2013, with a range of $677 TO 
$9022.  At their study site (LDS hospital in Salt Lake City), the authors estimated that over a 
4-ys period the excess hospital cost attributable to adverse drug events were $4,482,951 and 
the excess hospital days were 3874.  If 50% of these adverse drug events were preventable, 
then a successful prevention programme could save more than $500,000 annually (James et 
al., 2004).   
 It was observed in a case-controlled trial within a prospective co-hort study of 4108 
hospital admissions, 190 adverse drug events, of which 60 were preventable and the costs 
attributable to an adverse drug event were $2595 for all adverse drug events and $4685 for 
preventable adverse drug events.  The authors estimated that based on these data about the 
incidence of adverse drug events, the annual cost attributable to all adverse drug events, was 
equivalent to all health-care cost (Vikas Dhikav et al., 2004).  
The ADR reporting system 
 The World Health Organization Collaborating Centre for International Drug 
Monitoring was established in 1971 and since that the Centre collates spontaneous ADR 
reports from participating national centers with aims to increase the early recognition of new 
and unexpected ADRs.  By combining reports from many countries from all over the world, 
very rare adverse reactions can be detected (Dogra et al., 2013, Vikas Dhikav et al., 2004). 
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Blue Card System  
  In Australia, adverse reaction reporting is coordinated by the Adverse Drug 
Reactions Unit (ADRU) at the Therapeutic Goods Administration (TGA) and the system for 
monitoring adverse reactions is by voluntary reporting of events through health professionals 
and consumers.  When a health professional or consumer suspects an adverse reaction to a 
medicine, they can report it directly to the Adverse Drug Reaction Advisory Committee 
(ADRAC) using a “blue card” (Michael Bollen  2003). 
  Healthcare professionals usually submit reports on the ‘blue card’ which 
accompanies the Australian Adverse Drug Reactions Bulletin and the Schedule of 
Pharmaceutical Benefits (Michael Bollen, 2003).  Reports can also be made by letter, fax or 
electronically to http://www.tga.gov.au/problem/index.htm#medicines  
UK Yellow Card System (Scott et al., 2005) 
 The yellow card scheme for reporting suspected adverse drug reactions (ADRs) was 
introduced in 1964 and over 400,000 reports have now been received by the Committee on 
Safety of Medicines (CSM)/ Medicines and Healthcare products Regulatory Agency 
(MHRA). They also manage a spontaneous reporting system, which asks doctors and more 
recently, pharmacists to report all suspected reactions to new products marked with a black 
triangle in the British National formulary (BNF), the Association of British Pharmaceutical 
Industry (ABPI) Medicines Compendium and the Monthly Index of Medical Specialties 
(MIMS). Doctors and pharmacists are being asked to report all serious suspected reactions to 
established drugs (Scott et al., 2005). 
 Standard repot forms or Yellow Cards are located inside the back cover of the BNF, 
MIMS, ABPI medicines compendium and on prescription pads. The consent of the patient is 
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not required in order to submit a Yellow Card. The minimum details required for submission 
are the patient initials and an identification number, the identity of the reporting doctor or 
pharmacist, the nature, treatment and outcome of the suspected ADR and its start and stop 
dates, the seriousness of the reaction, all to be completed using tick boxes (Scott et al., 2005). 
Naranjo Causality Scale (adapted) (Naranjo et al., 1981) 
1. Are there previous conclusive reports on this reaction? 
Yes (+1) No (0) Do not know or not done (0) 
2. Did the adverse event appear after the suspected drug was given? 
Yes (+2) No (-1) Do not know or not done (0) 
3. Did the adverse reaction improve when the drug was discontinued or a specific 
antagonist was given? 
Yes (+1) No (0) Do not know or not done (0) 
4. Did the adverse reaction appear when the drug was readministered? 
Yes (+2) No (-1) Do not know or not done (0) 
5. Are there alternative causes that could have caused the reaction? 
Yes (-1) No (+2) Do not know or not done (0) 
6. Did the reaction reappear when a placebo was given? 
Yes (-1) No (+1) Do not know or not done (0) 
7. Was the drug detected in any body fluid in toxic concentrations? 
Yes (+1) No (0) Do not know or not done (0) 
8. Was the reaction more severe when the dose was increased, or less severe when the 
dose was decreased? 
Yes (+1) No (0) Do not know or not done (0) 
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9. Did the patient have a similar reaction to the same or similar drugs in any previous 
exposure? 
Yes (+1) No (0) Do not know or not done (0) 
Scoring 
 > 9 = definite ADR 
 5-8 = probable ADR 
 1-4 = possible ADR 
 0 = doubtful ADR 
Indian Scenario 
Monitoring of adverse drug reactions started in India about two decades ago (1982) under the 
chairmanship of the Drug Controller of India (DCI), five centers were established with the 
idea of starting a monitoring programme nationwide. It consisted of three phases in which the 
first one being monitoring of reactions in the institutes, second one in governmental bodies 
like Central Government Health Scheme (CGHS), and the third phase proposed to include 
general practitioners. A multi-institutional pilot study involving 58,194 cases was done in 
1987 under the aegis of Indian Council of Medical Research (ICMR). Its nodal centre 
(National Pharmacovigilance Centre) is located in the Department of Pharmacology, All 
India Institute of Medical Sciences, and New Delhi. It is affiliated to WHO collaborating 
Centre for ADR Monitoring, Uppsala, Sweden. The others are located in PGI (Chandigarh), 
JIPMER (Pondicherry), KGMC (Lucknow), and Seth GS Medical College (Mumbai) is the 
special centers. It was envisaged to be a collaborative activity of both clinicians and 
pharmacologists. Now in India, the pharmacologists with or without the involvement of 
clinicians usually have to observe it (Uppal et al., 2008). Physicians, however, continue to 
play a meaningful role in the entire monitoring process, as the co-operation of the clinicians 
is needed to have an access to the patient data and at times in interpretation of the reports of 
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suspected adverse drug reactions. In many other countries, the pharmacists or nurses usually 
carry out it under supervision. They are specially recruited for this purpose and the physicians 
and pharmacologists are involved in the interpretation of the collected data or hypothesis 
testing on the basis of the reports. These workers may involve a panel of the physicians in 
reviewing all the collected reports. Though the pattern of adverse reactions differs slightly 
from country to country, adverse reactions to analgesics (mainly, non-steroidal anti-
inflammatory drugs) and antibiotics constitute about half of all such reports in India (Uppal et 
al., 2008). This may be partly due to the fact that these are the most commonly used drugs in 
therapeutics. Another important drawback of clinical trials is that they can only report 
adverse reactions that appear within the finite duration of trial and delayed reactions would be 
missed. 
Pharmacovigilance (PV) 
Regulatory agencies, such as the US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA), have many responsibilities, including the protection and 
promotion of public health through the evaluation and supervision of medicines for human 
use (EMA guidelines, 2012).  
Pharmacovigilance is an important and integral part of clinical research. Despite its 40 
years history, pharmacovigilance remains a dynamic clinical and scientific discipline. It 
continues to play a crucial role in meeting the challenges posed by the ever increasing range 
and potency of medicines. When adverse effects and toxicity do appear especially, when 
previously unknown, it is essential that these are reported, analysed and their significance 
communicated effectively to an audience that has the knowledge to interpret the information, 
which carry an inevitable and some for all medicines there is a trade-off between the benefits 
and the potential for harm. The harm can be minimized by ensuring that medicines of good 
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quality, safety and efficacy are used rationally and that the expectations and concerns of the 
patient are taken into account when therapeutic decisions are made. Taking medicines and 
prescribing them are among the commonest of activities of people who are unwell and of 
those who care for them. It makes sense that those medicines should be monitored to equally 
demanding standards as those evident in the development and evaluation of drugs and that 
prescribing habits and the extent of rational and cost-effective use should be reviewed. 
Responsibility for the holistic approach to drug safety that is encompassed in the science and 
practice of pharmacovigilance as reflected in this article has to be shared if ideal practice is to 
be achieved. The scientists, clinicians, pharmaceutical manufacturers, drug developers, 
regulators, public policy makers, patients and the general public all have their own 
complementary roles in achieving what is envisaged.(Dogra et al., 2013). Pharmacovigilance 
is particularly concerned with adverse drug reactions, or ADRs, which are officially 
described as: "a response to a drug which is noxious and unintended, and which occurs at the 
doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the 
modification of physiological function (Santosh and Tragulpiankit, 2011) 
National Pharmacovigilance Programme (National Pharmacovigilance Protocol., 2004) 
  India has more than half a million qualified doctors and 15,000 hospitals having bed 
strength of 6, 24,000 and is the fourth largest producer of pharmaceuticals in the world. 
Now India is emerging as an important clinical trial hub in the world and many new drugs 
are being introduced by our country. Therefore, there is a need for a vibrant 
pharmacovigilance system in the country to protect the population from the potential harm 
that may be caused by some of these new drugs. 
Clearly aware of the enormity of task the Central Drugs Standard Control 
Organization (CDSCO) has initiated a well-structured and highly participative National 
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Pharmacovigilance Programme. It is largely based on the recommendations made in the 
WHO document titled Safety Monitoring of Medicinal Products-Guidelines for setting up 
and running a Pharmacovigilance centre. The National Pharmacovigilance Program was 
officially inaugurated by the Honorable Health Minister Dr. Anbumani Ramadoss on 23 
November, 2004 at New Delhi. 
 The specific aims of the pharmacovigilance programme are to contribute the 
regulatory assessment for benefit, harm, effectiveness and risk of medicines, encouraging 
their safe, rational and more effective (including cost effective) use. Further, to improve the 
patient care and safety in relation to use of medicines and to apply all medical and 
paramedical interventions for public health and safety. In spite of that it also promotes the 
better understanding, education and clinical training and its effective communication to the 
public.  
 The Programme aims to foster the culture of ADR notification in its first year of 
operation and subsequently aims to generate broad based ADR data on the Indian 
population and share the information with global health-care community through WHO-
UMC. Under this program, 26 peripheral centers, 5 regional centers and 2 zonal centers 
were established. The Peripheral centers are sharing the responsibility of recording the 
Adverse Events (AE) and also sending the information’s to the regional centers. They in 
turn collate and scrutinize the data received from the peripheral centers and submit it to the 
zonal centers and the zonal centers are analyzing the data and submitting consolidated 
information to the National Pharmacovigilance Center. The zonal centers are also providing 
the training, general support and coordinating the functioning as the regional centers 
(National Pharmacovigilance Protocol., 2004). 
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 The National Pharmacovigilance Advisory Committee (NPAC) oversee the 
performance of various zonal, regional and peripheral pharmacovigilance centers (PPC) as 
well as if necessary may recommend possible regulatory measures based on the data 
received from various centers. It also oversees data collection and assessment, 
interpretation of data as well as publication of ADR monitoring data. The Committee also 
periodically evaluates their protocol compliance levels to ensure that the data received is 
homogenous and can be scientifically pooled for informed regulatory decisions. Wherever 
necessary, NPAC also seeks the opinion of experts in various specializations. 
National Pharmacovigilance Policy 
 Since there are social and economic consequences of adverse drug reactions and the 
positive benefit/cost ratio implementing appropriate risk management, there is a need to 
engage health-care professional and the public at large, in a well-structured programme to 
build synergies for monitoring adverse drug reactions. The purpose of the programme is to 
collate data, analyze it and use the inferences to recommend informed regulatory 
interventions, besides communicating risks to healthcare professionals and the public.  
Medium-term objectives:  
To engage several healthcare professionals and NGOs in the drug monitoring and 
information dissemination processes. 
Long-term objectives:  
To achieve such operational efficiencies that would make Indian National 
Pharmacovigilance Programme a benchmark for global drug monitoring endeavors. Before 
a product is marked, experience of its safety and efficacy is limited to its use in clinical 
trials and the conditions under which patients are studied during the pre-marketing phase do 
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not necessarily reflect the way the medicine will be used in the hospital or in general 
practice once it is marked. Information about rare but serious adverse drug reactions, 
chronic toxicity, and the procedure of its use in special groups such as pregnant women, 
children and elderly are necessary.  
Aims of Pharmacovigilance (WHO, Pharmacovigilance: ensuring the safe use of 
Medicines, Geneva, WHO 2004.) 
 Improve patient care and safety in relation to the use of medicines, all medical and 
Para medical interventions. 
 Research the efficacy of drug and by monitoring the adverse effects of drugs right 
from the lab to the pharmacy and then on for many years. 
 Pharmacovigilance keeps track of any drastic effects of drugs. 
 Improve public health and safety in relation to the use of medicines. 
 Contribute to the assessment of benefit, harm, effectiveness and risk of medicines, 
encouraging their safe, rational and more effective (including costeffective) use. 
 Promote understanding, education, clinical training in pharmacovigilance and its 
effective communication to the public 
Pharmacovigilance impact on diabetes mellitus treatment 
Following table and figure represents the impact of pharmacovigilence on diabetes mellitus 
treatment and diabetes drug development (Bailey, 2013). Considering all the above factors, it 
is essential to monitor the adverse drug reactions through Pharmacovigilance program for 
diabetes mellitus treatment.  
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Diabetes mellitus is the commonest endocrine disorder that affects more than 100 
million people worldwide (6% of the population) and in the next 10 years it may affect about 
five times more people that it does now (WHO/Acadia, 1992; ADA, 1997). In India, the 
prevalence rate of diabetes is estimated to be 1-5% (Patel et al., 1986; Rao et al., 1989). 
Complications are the cause of mortality and morbidity in diabetes mellitus (DM). DM alone 
ranks the top ten causes of death in Western nations, and despite important improvements in 
its clinical management to date it has not been possible to control significantly its lethal 
consequences.  
Diabetes mellitus 
 A study of ancient literature indicates that diabetes was fairly well known and well-
conceived as an entity in India. The knowledge of the system of the diabetes mellitus, as the 
history reveals, existed with the Indians since prehistoric age. Sushruta has accurately 
described diabetes around 1000 B.C. The disease was known as ‘Asrava’ during Vedic era 
(6000 B.C.) and a detailed description of it is available in Brahattrai viz.; Charaka Samhita, 
Susruta Samhita and Babhatta. Asthanga haridaya (600 AD) is the first medical treatise in 
which one gets clear definition of madhumeha/diabetes mellitus mentioning it as glycosuria 
(Madhviv mehati i.e. honey like urine). The word ‘Prameh’ (diabetes) is derived from the 
root ‘Miha sechane’ meaning of passing urine, qualify by prefix ‘pra’ meaning excess in both 
frequency and quantity [Prameha = Pra (excessive) + Meha (urination)] (Kohli, 1994). This 
derivation of word is again substantiated when the clinical features of ‘Prameha’ are 
described as ‘Prabhuta-mutrata’ and ‘Avil Mutrata’ i.e. excessive urination with increased 
turbidity of urine. The whole description of diabetes from the etiology, pathogenesis, clinical 
features, complications and management all look to be comparable with the syndrome of 
diabetes mellitus as known in modern medicine.  
Literature Review   Page 33  
 
The diabetes mellitus (DM) can be divided into three major subclasses i) type 1 
diabetes mellitus, ii) type 2 diabetes mellitus and iii) Gestational diabetes, normally occurs 
during pregnancy may also lead to diabetes after delivery in some cases. 
Type 1 diabetes mellitus: 
Type 1 diabetes (previously known as insulin dependent diabetes mellitus; IDDM) is 
characterized by beta cell destruction by an autoimmune process usually leading to absolute 
insulin deficiency and acute onset, usually before 25 years of age (Jennifer Mayfield, 1998). 
Although the etiology is unknown, human leukocyte antigen association, viral factors and 
various environmental factors may contribute (Watkins and Sanders, 1995). Symptoms of 
type 1 diabetes usually develop over a short period, although beta cell destruction can begin 
years earlier. Symptoms may include increased thirst and urination, constant hunger, weight 
loss, blurred vision and extreme fatigue. If not diagnosed and treated with insulin, a person 
with type 1 diabetes can lapse into a life-threatening diabetic coma, also known as diabetic 
ketoacidosis.  
Type 2 diabetes mellitus:  
 Type 2 diabetes mellitus (previously known as non-insulin dependent diabetes 
mellitus; NIDDM) is characterized by insulin resistance in peripheral tissue and insulin 
secretory defect of the beta cell (Jennifer Mayfield, 1998). This is the most common form of 
diabetes mellitus and is highly associated with a family history of diabetes, older age, obesity 
and lack of exercise. Defective beta cells become exhausted, further fueling the cycle of 
glucose intolerance and hyperglycemia. The etiology of type 2 diabetes mellitus is 
multifactorial and probably genetically based, but it also has strong behavioral components. 
The symptoms of type 2 diabetes develop gradually. Their onset is not as sudden as in type 1 
diabetes. Symptoms may include fatigue, frequent urination increased thirst and hunger, 
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weight loss, blurred vision and slow healing of wounds or sores. Type 2 diabetes has strong 
genetic influences and occurs in identical twins with almost total concordance (Barnett et al., 
1981; Leslin and Pyke, 1987). β cell mass is relatively well preserved but insulin secretions in 
response to specific secretogogues is reduced and clean evidence exists for resistance to 
insulin action in peripheral tissues (Gepts, 1984; DeFronzo, 1988; Savage et al., 1975; Porte, 
1991).  The plasma insulin level in type 2 diabetes patients are higher than or equal to that of 
non-diabetic control subjects (Yalow and Berson, 1960). This suggests that type 2 DM results 
from insulin resistance rather than insulin deficiency. However, it has become clear that both 
insulin resistance (Kahn, 1994) and insulin deficiency come in to play to cause 
hyperglycemia in type 2 DM patients. Abnormal regulation to glucose metabolism in the liver 
and impaired glucose tolerance was seen after an oral glucose load in type 2 DM subjects 
(Thorburn et al., 1995). Conditions associated with the development of insulin resistance, 
especially obesity and advancing age; greatly increase the risk of type 2 DM. Insulin 
resistance co-relates with certain patterns of obesity and is greater in individuals with central 
obesity than in those with more generalized obesity (Kissebah et al., 1982). Insulin resistance 
and hyperinsulinemia may also be associated with hypertension and hypertriglyceridemia, 
decreased-high density lipoprotein (HDL) cholesterol and increased risk of atherosclerosis 
and cardiovascular disease (Reaven, 1988; Karam, 1992). 
Gestational diabetes  
Some women develop gestational diabetes late in pregnancy, though this form of 
diabetes usually disappears after the birth of the baby. However, women who have had 
gestational diabetes have a 20-50 % chance of developing type 2 diabetes within 5 to 10 
years. As with type 2 diabetes, gestational diabetes occurs more often in some ethnic groups 
and women with family history of diabetes. Gestational diabetes is caused by hormones of 
pregnancy or a shortage of insulin. Women with gestational diabetes may not experience any 
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symptoms. Infants of mother with gestational diabetes are vulnerable to several chemical 
imbalances such as low serum calcium and low serum magnesium levels but in general there 
are two major problems of gestational diabetes i) macrosomia and ii) hypoglycemia. For 
mother the complications like hypertension, pre-eclampsia and increased risk for developing 
type 2 diabetes mellitus and for baby macrosomia, hypoglycemia, jaundice, low calcium and 
magnesium respiratory distress syndrome, increased risk for childhood and adult obesity and 
risk for type 2 diabetes may occur (ADA, 2002) 
Drugs treatment for diabetes mellitus: 
Insulin:  
Insulin is a hormone which helps to regulate blood sugar. A number of different types 
of insulin are available as medication, with some insulins acting for as long as a day and 
others acting for only a few hours. However, insulin is prescribed for people with type 1 
diabetes and for people with type 2 diabetes who have not responded so well on oral 
medication (tablets). Insulin is the first line therapy for type-1 diabetes mellitus. There are 
different classification of Insulin like short acting, long acting, intermediate acting and rapid 
acting insulin. It is prescribed at 100-U i.e. 100 units per milli liter and 40 units per milli liter 
strengths. (Goodman & Gilman’s, 2006)  
Biguanides / Metformin 
The only available diabetes medication in the biguanides class of drugs is metformin. 
Biguanides prevent the liver from producing glucose and helps to improve the body’s 
sensitivity towards insulin. Metformin is commonly used as a first line treatment for type 2 
diabetes and may occasionally be prescribed, in combination with insulin, for people with 
type 1 diabetes. Metformin was approved in 1994 (in the USA) and is prescribed as; 500mg 
tablets,850mg tablets, 500mg modified-release tablets, 750mg modified-release tablets, 1g 
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modified-release tablets, 1g oral powder sachets sugar free, 500mg oral powder sachets sugar 
free 500mg/5ml oral solution sugar free. (Goodman & Gilman’s, 2006) 
Sulphonylureas 
Sulphonylureas are the class of antidiabetic drug for type 2 diabetes that tends to 
include those drugs which end in ‘ide’. The following drugs are all in the sulphonylureas 
class (branded names in brackets): Glibenclamide –also known as Glyburide (Daonil), 
Glipizide (Glucotrol), Gliquidone (Glurenorm), Glyclopyramide (Deamelin-S), Glimepiride 
(Amaryl) Gliclazide (Diamicron), Sulphonylureas work by increasing the amount of insulin 
the pancreas produces and increasing the working effectiveness of insulin. The mode of 
action of sulphonylureas means that hypoglycemia and weight gain can be relatively common 
side effects. (Goodman & Gilman’s, 2006) 
Meglitinides / Prandial glucose regulator / Glinides 
The glinides are a class of drug which have a similar response as sulphonylureas but 
act for a shorter time. Meglitinides are prescribed to be taken by people with type 2 diabetes 
within half an hour before eating. As the drugs act for a shorter period than sulphonylureas, 
the side effects of hypoglycemia and weight gain have a smaller likelihood. e.g Repaglinide 
(Prandin),Nateglinide (Starlix) (Goodman & Gilman’s, 2006) 
Alpha-glucosidase inhibitors 
Alpha-glucosidase inhibitors, such as acarbose (marketed as Precose or Glucobay) or 
miglitol (branded as Glyset) are drugs for type 2 diabetes which slow down the digestion of 
carbohydrates in the small intestine and therefore can help to reduce after meal blood sugar 
levels. (Goodman & Gilman’s, 2006) 
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Thiazolidinedione / Glitazones 
Thiazolidinediones, also known as glitazones, are a medication for type 2 diabetes 
which helps to improve insulin sensitivity and have been found to help decrease triglyceride 
levels.  However, these have recently been in public spotlight as questions over their long 
term safety. In September 2010, the most popularly prescribed drug in this class rosiglitazone 
(Avandia) was banned for use by the European medicines Agency over heart attack concerns. 
Pioglitazone (Actos) has also made the news in connection with instances of bladder cancer, 
however, the danger has not been deemed sufficient to need to ban the drug in the UK. 
Pioglitazone works by making cells more sensitive to insulin, which is used to regulate the 
level of glucose in the body. Improving insulin sensitivity (or reducing insulin resistance) 
makes it easier for sugar (glucose) in the blood to get into the cells. Pioglitazone is 
administered orally with or without food. The drug is available in 15 mg, 30mg and 45mg 
tablet doses. Among older patients with diabetes, pioglitazone is associated with a 
significantly lower risk of heart failure and death than is rosiglitazone. Given that 
rosiglitazone lacks a distinct clinical advantage over pioglitazone, continued use of 
rosiglitazone may not be justified. (Goodman & Gilman’s, 2006, Juurlink et al, 2009) 
DPP-4 inhibitors / Gliptins 
DPP-4 inhibitors, also known as gliptins, are a class of drug which help to stimulate 
the production of insulin and reduce the production of glucagon, particularly during 
digestion. DPP-4 inhibitors are usually prescribed for people with type 2 diabetes who have 
not responded well to drugs such as metformin and sulphonylureas. This drug class includes 
following medications (trade names in brackets): Sitagliptin (Januvia), Vildagliptin (Galvus), 
Saxagliptin (Onglyza), Linagliptin (Tradjenta) –approved for use in the USA. Sitagliptin 
works by inhibiting the DPP-4 enzyme that destroys GLP and GIP hormones, allowing both 
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to function more effectively. Both glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP) are released by the intestine and affect blood glucose levels. 
When more of these hormones are released blood sugar levels are reduced. It is available as 
100mg tablets in the market. (Goodman & Gilman’s, 2006) 
Incretin mimetics / GLP-1 analogues 
Incretin mimetics, also known as GLP-1 analogues, are an injectable treatment for 
type 2 diabetes. Incretin mimetics look to mimic the effect of a group of hormones called 
incretins which increase the production of insulin and decrease the release of glucagon in a 
relatively similar way DPP-4 inhibitors. This is not a coincidence as the way DPP-4 
inhibitors work is to prevent the protein dipeptidyl peptidase-4 from destroying the incretin 
hormones. GLP-1 analogues have been found to be particularly effective in helping to 
improve blood glucose levels and helping with weight loss. The following GLP-1 analogues 
are prescribed in the UK (branded names in brackets): Exenatide (Byetta) and Liraglutide 
(Victoza). (Goodman & Gilman’s, 2006) 
Amylin analogues 
Amylin is a hormone produced by the pancreas and released at the same time as 
insulin, but in much smaller quantities (about 1% compared with insulin). Amylin helps to 
suppress glucagon release and therefore reduce post meal blood glucose levels. Pramlintide 
acetate (marketed as Symlin) is available in the US as an injectable drug for the treatment of 
both type 1 and type 2 diabetes.The use of amylin with insulin can carry an increased chance 
of hypoglycemia. (Goodman & Gilman’s, 2006) 
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3. AIMS AND OBJECTIVE 
 
Aim of the study is to record and assess the adverse drug reactions during the treatment of 
diabetes mellitus in territory hospital. 
 
The main objective of this study is to communicate the reported adverse reactions with 
through analysis (age wise, body weight wise, gender wise etc using WHO and Naranjo’s 
analysis). These reports can act as an reference for future diabetic treatment with the label 
warning. All these exercise is expected to reduce the adverse drug reactions for future course 
of action. 
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4. PLAN OF WORK 
 
The work was planned in such a way that to visit the Krishnagiri Government General 
hospital, Tamilnadu and meet the respective clinicians to get the information about the 
diabetes mellitus treatment by various classification of anti-diabetic drugs. It was also 
planned to interact with the patient or patient’s attendant (who accompany the patient may be 
relative or friends) and record the adverse drug reactions including the symptoms and degree 
of severity of the adverse drug reaction encountered by them during the course of treatment. 
Along with severity of adverse drug reactions the patient counselling given by pharmacist, 
pharmacologist and clinicians to be recorded. These informations will also be collected from 
the interns, post graduate students, nurses. It was also planned to collect the respective bio-
chemical analysis reports of the patients to know the severity of the disease progression, 
family history etc.  
The work to be initiated from October, 2013 to December, 2013, i.e. close to three 
months for patient interaction and data collection. Next one month for assessment of the data 
collected using various causality assessment forms. Finally to prepare the report and share 
with regional pharmacovigilance centre.  
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5. METHODOLOGY 
  The study was conducted in Krishnagiri Government General Hospital, 
Tamilnadu.  
STUDY PERIOD 
This study which includes spontaneous prospective monitoring, reporting and 
documenting of ADRs of Diabetic patients undergoing various treatments was carried 
out for a period of 4 months (October, 2013 to January, 2014) by me on both in-
patients and out-patients.  
STUDY PROCEDURE 
All the necessary and relevant data were collected from diabetes patients such as 
case notes, treatment charts, laboratory data reports, ADRs notification forms, with 
the help of patient’s interview as well as reporter interview and the observations were 
recorded in ADR assessment form (Note: since we do not administer any drug to the 
patients during the assessment period, there was no need for consent form). The ward 
was visited almost daily during the study period and ADR assessment form were kept 
in the medication record with the aim that if any ADR alert is given in the ADR 
assessment form by the doctor or the nurses it will be noted and the data regarding 
ADR will be collected from patient record and were documented.  
A suitable ‘ADR reporting card’ was designed based on the similar to the ‘Blue 
Card’ (Australian adverse drug reaction advisory committee) and ‘Yellow Card’ (UK 
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system of reporting ADRs) and was named as ‘Pink Card’ (Indian system of reporting 
ADRs) along with the necessary changes for the present study.  
INCLUSION CRITERIA 
 
 Both the type-1 and type-2 diabetes patients were included 
 Both in-patients and out-patients were included in the study 
 All the diabetic patients of different age groups were included. 
 The physiological reaction of diabetic patients due to the drug alone were 
included 
 Both male and female genders were included. 
 Patients with diabetes along with cardiovascular disease, pulmonary infection and 
renal failure patients were also included. 
 Patients taking all category medicines (diabetes drugs classification) 
  The ADRs of all types were also included. 
EXCLUSION CRITERIA 
 The patients left the therapy without following medical advice (non compliance) 
 The physiological reaction due to the disease (diabetes) 
 Self-medication, prescriptions followed from non-qualified person. 
 The ADRs due to other class of anti-diabetic drugs along with lipid lowering 
drugs like atorvastatin.  
 The patients not willing to give consent for this study. 
 The patients taking other system of medicine (siddha, ayurvedha, unani)  
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 The ADRs suspected due to co-administered drug used to treat other 
complications. 
 The ADRs reported by patients on oral interview without any support of 
investigations.  
 Allergic reaction due to pollens, dust and insects. 
DOCUMENTATION OF ADRs 
 
ADR monitoring form was designed and was implemented in the diabetic wards 
and also out-patient departments. If a suspected ADR was reported and had met the 
inclusion criteria, data on that particular suspected drug and reaction were collected and 
documented in a suitably designed ADR documentation form. Oral consent was taken 
from patients, their relatives (who accompany the patient for treatment) and concern 
doctors for further interviewing to collect data such as description of ADR and also 
permission to collect data. 
All the relevant data which includes the drugs received by the patient prior to onset of 
reaction, their respective dosage, route of administration with frequency, date of onset of 
reaction and patient’s allergy history were noted. The relevant date of drugs which were 
taken by patients prior to onset of reaction, like dosage, route of administration and its 
frequency were also recorded. 
 
 
VARIOUS FORMS DESIGNED FOR DOCUMENTING ADR 
 Notification of a suspected adverse drug reaction (ADR) 
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 Adverse drug reaction assessment form. 
 Documentation form  
 
ASSESSMENT OF ADRs 
 
ADRs are assessed through Naranjo’s causality assessment scale, new algorithm 
to identify the causality of ADRs, and WHO causality assessment scale. Depending on 
the questionnaire in the assessment form, ADRs were categorized as definite, probable, 
possible and unlikely. In case of Naranjo’s, new algorithm scale and in the case of WHO 
probability scale depending on the questionnaire it was categorised as certain, probable, 
possible, unassessable/unclassified, unlikely, and conditional/unclassified. 
 
The various forms for assessing ADRs were: 
 Naranjo’s causality assessment scale  
 WHO causality scale  
 New algorithm to identify the causality of ADRs  
 
The questions present in the above forms were directy asked to the patients during the 
oral interview or it was recorded form the patient case sheets present in the ward during 
treatment. The cunsultation with concern doctor was also taken into consideration in 
relation to  documentation of the ADRs. 
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PANEL OF JUDGES 
The patient’s case notes were reviewed independently by doctors and pharmacists 
and the panel of reviewers selected was consisted of 2 doctors of general medicine and 2 
pharmacologists. The evaluation of the ADR monitoring and assessing causality was 
done by this panel. During the ward rounds if the physician required the consultation of 
other members of the health care team then it was also taken into consideration and on 
certain occasions the pharmacist’s suggestions were recommended.  
The recommendations were as follows: 
 Prevision of drug information relevant to the suspected ADRs to the notifying 
doctor as a part of primary patient care.  
 Educate the patient about the event of ADRs and prevention of further reactions 
recommendation of alternative therapy and identification of drug reaction.  
 “Systems error” and drug allergy. 
 
REPORTING ADRs TO NATIONAL PHARMACOVIGILANCE CENTRE 
The data regarding ADRs were collected and documented from the patient 
medication history, patient case notes, treatment charts, laboratory data reports, patient 
interview, and patient reporter interview. The data collected will be reported to national 
pharmacovigilance centre through peripheral pharmacovigilance centre.  
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6. RESULTS AND DISCUSSION 
6.0 RESULTS 
The study was performed among the diabetes mellitus patients visited to the endocrine 
(diabetology) centre of territory hospitals and diabetic care clinics. The study was conducted 
for suspected ADRs in 118 patients. Among 118 patients, 14 patients were excluded from the 
study due to not following the medical advice, left the therapy without medical advice, 
patients shifted to other diabetes care clinics due to convenient of the patients so finally the 
104 ADRs of diabetes mellitus treatment was evaluated and reported.  
 
Out of 104 ADRs, the in- patients were 40 (38%) and the out patients were 64 (62%) (Table 
6.1 & Figure 6.1). The sex wise distribution of diabetes mellitus patients showed that the 
male in patients and out patients numbers were 20 (42%), 28 (58%) respectively whereas in 
the case of females it was 26 (46%) for in patients and 30 (54%) for out- patients. It was 
observed that the out-patients were more suspected for ADRs in diabetes mellitus (Table 6.2 
& Figure 6.2) 
 
Table: 6.1 
The incidence of ADRs in male and female patients 
S.No Gender No. of ADRs Percentage 
1 Male 48 46.15 
2 Female 56 53.85 
 
 
Results and Discussion                                                                         Page 47  
 
 
 
Figure: 6.1 
The incidence of ADRs in male and female patients 
 
 
 
Table 6.2 
Distribution of ADRs in both in-patients and out-patients 
S.No 
Types of 
ADRs 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 In patient 40 38.46 20 41.67 26 46.42 
2 Out patient 64 61.53 28 58.33 30 53.57 
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Figure: 6.2 
Distribution of ADRs in both in-patients and out-patients (gender wise) 
 
 
 
6.1 WEIGHT DISTRIBUTION  
 
The maximum ADRs were found in the weight group of 61 kg or above and in this weight 
group 60 (60%) patients were  reported ADRs amongst which 28 (58%) were male and 34 
(61%) were female. In the weight group of 0-20 the number of ADRs were 3(3%) in which 
2(4%) were male and 1(2%) were female respectively. The weight group of 21-40 the ADRs 
were reported 7(7%) amongst which 3(6%) were male and 4 (7%) were female. Further, 41-
60 weight group is the second dominated weight group had 32(31%) of ADRs in which male 
were 15(31%) as well as female were 17(30%) respectively (Table 6.3 & Figure 6.3) 
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Table: 6.3 
Weight distribution of ADRs in both the genders 
S.No Weight (in Kg) 
Number of 
ADRs 
% of ADRs 
Sex Distribution 
Male % Female % 
1 0 – 20 3 2.88 2 4.17 1 1.78 
2 21 – 40 7 6.73 3 6.25 4 7.14 
3 41 – 60 32 30.77 15 31.25 17 30.36 
4 61 – above 62 59.61 28 58.33 34 60.71 
 
 
 
Figure: 6.3 
Weight distribution of ADRs in both the genders 
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6.2 AGE DISTRIBUTION  
   
The suspected ADRs individual were categorized in to different group wise <=10,10-20,20-
30,30-40,40-50and >=50. The age group of 30-40 reported highest numbers of ADRs 
42(40%), in which the male patients were 19(40%) and the female number of patients were 
23(41%). The second dominant age group were 40-50 in this 20(19%) of patients reported 
ADRs and the number of ADRs were 9 (19%) in male and the number of ADRs were 11 
(20%) female. The third place of highest ADRs numbers found in the age group of 20-30 
where 8 (17%) were male patients and the number of ADRs were 18(17%) whereas the 
female number of ADRs were 10 (18%). Further the age group of >=50 were shows a total 17 
(16%) ADRs amongst which the male patients were 8 (17%) and the female patients were 9 
(16%). The age group of <=10 shows 3(3%) of ADRs in which the male number of ADRs 
were 2 (4%) and the female number of ADRs 1(2%). The age group of 10-20 were reported 
with ADRs of 4(4%) along with almost equal representation of male and female contribution 
2(4%), 2(4%) respectively (Table 6.4 & Figure 6.4). Table 6.5 represents the Age wise 
contribution of male and female patients.     
  
Results and Discussion                                                                         Page 51  
 
 
Table: 6.4 
Age wise distribution of ADRs in both the genders 
S.No Age (years) 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 <10 3 2.88 2 4.17 1 1.78 
2 10 – 20 4 3.85 2 4.17 2 3.57 
3 20 – 30 18 17.31 8 16.67 10 17.86 
4 30 – 40 42 40.38 19 39.58 23 41.07 
5 40 – 50 20 19.23 9 18.75 11 19.64 
6 >50 17 16.35 8 16.67 9 16.07 
 
 
Figure: 6.4 
Age wise distribution of ADRs in both the genders 
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Table: 6.5 
Table showing the age wise percentage contribution of ADRs 
 
Age (years) 
Male 
(Percentage; %) 
Female 
(Percentage; %) 
Total 
(Percentage; %) 
<10 
2 
(66.67) 
1 
(33.33) 
3 
(100.0) 
10 – 20 
2 
(50.0) 
2 
(50.0) 
4 
(100.0) 
20 – 30 
8 
(44.44) 
10 
(55.56) 
18 
(100.0) 
30 – 40 
19 
(45.24) 
23 
(54.76) 
42 
(100.0) 
40 -50 
9 
(45.0) 
11 
(55.0) 
20 
(100.0) 
>50 
8 
(47.06) 
9 
(52.94 
17 
(100.0) 
Total 
48 
(46.15) 
56 
(53.85) 
104 
(100.0) 
 
 
6.3. 95% CONFIDENCE INTERVALS OF AGE & WEIGHT 
The 95% confidence intervals of age showed 33.95 to 38.10 and at the same time the 
confidence interval of weight showed 55.7 to 61.01. The mean of age was 36.03 and the 
standard error of mean was 1.04 and at the same time the mean weight of 104 patients was 
58.39 and the standard error of mean was 1.32 (Table 6.6 & Figure 6.5).     
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Table: 6.6 
Table showing 95% confidence intervals of age and weight 
Variable Observation Mean Std. Err. 95% confidence interval 
Age 104 36.03 1.044 33.9584 38.1061 
Weight 104 58.39 1.32 55.7567 61.0175 
 
 
Figure: 6.5 
Figure showing 95% confidence interval analysis of Age and Weight parameters 
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6.4 STATISTICAL ANALYSIS OF AGE AND WEIGHT  
The standard deviation of age and weight were 10.06 and 12.77 respectively and the median 
of age and weight was 36 and 62 respectively (Table 6.7 & Figure 6.6).  
 
Table: 6.7 
Table showing the Statistics of age and weight 
Statistics Age Weight 
Mean 36.0323 58.3871 
Median 36 62 
Standard deviation 10.0698 12.7723 
Standard error mean 1.0442 1.3244 
 
 
Figure: 6.6 
Figure showing the Statistics of Age and Weight 
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6.5 MANAGEMENT OF ADRs 
 
The ADRs managed in the study area was done in 3 ways, they are withdrawn the drug, just 
altering the dose of the drug, and by no change in the diabetes mellitus. From the reported 
ADRs the management step taken by withdrawing the drug from 52 (50%) patients in which 
male were 25 (52%) and the female were 27 (48%). The drug dose altered patients were 6 
(6%) in which the male patients were 2 (4%) and the female patients was 4 (7%). The 
unaltered therapy was observed in total 46 (44%) patients amongst which the male were 21 
(44%) and the female were 25 (45%) (Table 6.8 & Figure 6.7) 
 
Table: 6.8 
Management of ADRs in the Hospital 
S.No Management 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 Drug Withdrawn 52 50.0 25 52.08 27 48.21 
2 Dose Altered 6 5.77 2 4.17 4 7.14 
3 No Change 46 44.23 21 43.75 25 44.64 
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Figure: 6.7 
Management of ADRs in the Hospital 
 
 
6.6 SEVERITY OF REPORTED ADRs 
The severity of ADRs from the reported patients were mild 16 (15%), moderate 77 (74%), 
severe 9 (9%) and the lethal was 2(2%). The ADRs were dominant in the moderate class 
whereas mild class shows the second place (Table 6.9& Figure 6.8). 
Table: 6.9 
Table showing severity of reported ADRs 
S.No Severity 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 Mild 16 15.38 7 14.58 9 16.07 
2 Moderate 77 74.03 36 75.0 41 73.21 
3 Severe 9 8.65 4 8.33 5 8.93 
4 Lethal 2 1.92 1 2.08 1 1.78 
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Figure: 6.8 
Figure showing severity of reported ADRs 
 
 
 
6.7 NARANJO’S CAUSALITY ASSESSMENT OF ADRs 
 
From the reported ADRs of 104 patients the Naranjo’s causality assessment shows the 
‘definite’ number of ADRs were 54 (52%) in which the male patients ADRs were 25 (52%) 
and the female patients ADRs were 29 (52%). The scale ‘probable’ number of ADRs were 36 
(35%) in which male were 17 (35%) and the female were 19 (34%). The ‘possible’ was 
reported with 10 (10%) patients in which male patients were 4 (8%) and the female patients 
were 6 (11%). The ‘unlikely’ reported was in only 4 (4%) patients in which male patients 
were 2 (4%) and the female patients were 2 (4%) respectively (Table 6.10 & Figure 6.9). 
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Table: 6.10 
Table showing Naranjo’s causality assessment of ADRs 
S.No Causality 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 Definite 54 51.92 25 52.08 29 51.78 
2 Probable 36 34.62 17 35.42 19 33.92 
3 Possible 10 9.61 4 8.33 6 10.71 
4 Unlikely 4 3.85 2 4.17 2 3.57 
 
 
 
Figure: 6.9 
Figure showing Naranjo’s causality assessment of ADRs 
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6.8. WHO PROBABILITY ASSESSMENT OF ADRs 
  
The ADRs assessed by WHO probability scale showed the results and 65 (63%) patients were 
in ‘certain’ group which includes 31 (65%) of male patients and 34 (61%) of female patients. 
The ‘probable’ was observed in 27 (26%) of patients in which the 12 (25%) were male 
patients and 15 (27%) were females patients. The ‘possible’ were reported with 4 (4%) 
patients in which the male patient were 2 (4%) and the female patients were 2 (4%). The 
‘Unclassified / unassessable was reported with 5 (5%) patients and amongst these the male 
and female patients were 2 (4%), 3 (5%) respectively. The ’unlikely’ was reported with 2 
(1.9%) in which male 1 (2%) and female 1 (1.8%). Finally, conditional/un-classified was 
reported with 1 ADR which contributes 0.96% in which no male and 1 (1.8%) female 
contribution was there. (Table 6.11 & Figure 6.10)  
 
Table: 6.11 
Table showing WHO probability assessment of ADRs 
S.No 
WHO 
probability 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 Certain 65 62.50 31 64.58 34 60.71 
2 Probable 27 25.96 12 25.00 15 26.78 
3 Possible 4 3.85 2 4.17 2 3.57 
4 
Unclassified/un
-assessable 
5 4.80 2 4.17 3 5.36 
5 Unlikely 2 1.92 1 2.08 1 1.78 
6 
Conditional/un-
classified 
1 0.96 0 0.0 1 1.78 
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Figure: 6.10 
Figure showing WHO probability assessment of ADRs 
 
 
 
6.9 ASSESSMENT OF ADRs THROUGH NEW ALGORITHM 
 
The new algorithm shows ‘possible’ was the highest number 48 (46%) in which the males 
were 22 (46%) and the females were 26 (46.4%). The ‘probable’ shows the second highest 
with 38 (37%) patients and group the males were 17 (35.4%) female’s were 21 (38%). The 
‘definite’ shows 16 (15%) patients and amongst these the males were 8 (17%) and the 
females were 8 (14%). In the ‘unlikely’ group, a total reported ADRs was 2 (1.9%) amongst 
which the males were 1 (2%) and females were 1 (1.8%) respectively (Table 6.12 & Figure 
6.11). 
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Table: 6.12 
Table showing assessment of ADRs through new algorithm 
S.No 
New algorithm 
(Causality) 
Number 
of ADRs 
% of 
ADRs 
Sex Distribution 
Male % Female % 
1 Definite 16 15.38 8 16.67 8 14.28 
2 Probable 38 36.54 17 35.42 21 37.50 
3 Possible 48 46.15 22 45.83 26 46.43 
4 Unlikely 2 1.92 1 2.08 1 1.78 
 
 
 
Figure: 6.11 
Figure showing assessment of ADRs through new algorithm 
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6.10 THE DRUG AND ADRs RATIO 
The highest rate of ADRs were reported in ‘Insulin’ 34 (33%) treated patients whereas the 
second highest ADRs was associated with ‘Metformin’ 28 (27%). The number of patients 
were present in the ‘Gliclazide’ was 19 (18.3%). The ‘Pioglitazone’ reported with 15 (14.4%) 
of patients and the ‘Sitagliptin’reported with 8 (7.7%) patients (Table 6.13 & Figure 6.12). 
Table 6.14 represents the reported adverse drug reactions for diabetes mellitus treatment 
classification. 
Table: 6.13 
Table showing the drugs and ADRs ratio 
S.No Drugs Number of ADRs Percentage 
1 Metformin 28 26.92 
2 Gliclazide 19 18.27 
3 Insulin 34 32.69 
4 Pioglitazone 15 14.42 
5 Sitagliptin 8 7.69 
6 Total 104 100.0 
 
Figure: 6.12 
Figure showing the drugs and ADRs ratio 
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Table: 6.14 
Table showing reported adverse drug reactions 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 Diarrhea 29 27.88 
2 Nausia/Vomiting 4 3.85 
3 Flatulence 4 3.85 
4 Asthenia 3 2.88 
5 Indigestion 2 1.92 
6 Abdominal discomfort 2 1.92 
7 Headache 4 3.85 
8 Lactic acidosis 2 1.92 
9 Renal impairment 2 1.92 
10 Hypoglycemia 4 3.85 
11 Rash/Erythemia 1 0.96 
12 Taste disorder 1 0.96 
13 Sweating  1 0.96 
14 Palpitation 1 0.96 
15 Hypertension 4 3.85 
16 Impaired Hepatic functions 4 3.85 
17 Dehydration 2 1.92 
18 Hyperkalaemia 1 0.96 
19 Malaise  1 0.96 
20 Urinary incontinence 3 2.88 
21 Hyponatraemia 2 1.92 
22 pancreatitis 4 3.85 
23 Anuria 1 0.96 
24 Dyspepsia 1 0.96 
25 Hypothermia 2 1.92 
26 Pyrexia 2 1.92 
27 Oedema peripheral 3 2.88 
28 Haemolytic Anaemia 1 0.96 
29 Dyspnoea 1 0.96 
30 Face oedema 1 0.96 
31 Dizziness 1 0.96 
32 Fatigue 2 1.92 
33 Vision problems 1 0.96 
34 Weight gain 5 4.81 
35 Congestive heart failure 2 1.92 
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6.11 REPORTED ADRs OF METFORMIN 
The highest number of Metformin treated patients reported with diarrhea (21.4%) and the 
second AE was nausea/vomiting and the number of patients were 2 (7.4%). Along with this 
nausea/vomiting equal number of cases were reported for the following adverse events i.e. 
Flatulence, Headache, Renal impairment, Taste disorder and Impaired Hepatic functions. 
These AE were accounted for 2 patients each contributing with 7.4%. The third most reported 
AE were Asthenia, Indigestion, Abdominal discomfort, Lactic acidosis, Hypoglycemia, Rash, 
Palpitation and Dehydration. They contribute each 1 patient which accounts for 3.57% each 
to the AE. (Table 6.15 & Figure 6.13) 
Table: 6.15 
Table showing Reported ADRs of Metformin 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 Diarrhea 6 21.43 
2 Nausia/Vomiting 2 7.14 
3 Flatulence 2 7.14 
4 Asthenia 1 3.57 
5 Indigestion 1 3.57 
6 Abdominal discomfort 1 3.57 
7 Headache 2 7.14 
8 Lactic acidosis 1 3.57 
9 Renal impairment 2 7.14 
10 Hypoglycemia 1 3.57 
11 Rash/Erythemia 1 3.57 
12 Taste disorder 2 7.14 
13 Sweating  1 3.57 
14 Palpitation 1 3.57 
15 Hypertension 1 3.57 
16 Impaired Hepatic functions 2 7.14 
17 Dehydration 1 3.57 
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Figure: 6.13 
Figure showing reported ADRs of Metformin 
 
 
 
 
6.12 REPORTED ADRs OF GLICLAZIDE 
 
The Gliclazide treated patients reported highest number of AE with pancreatitis 3 (15.8%) 
and the Headache, Renal impairment, Hypoglycemia, Impaired hepatic functions and weight 
gain were seen with 2 (10.5%) of the Gliclazide treatment, whereas, the Nausia/vomiting, 
Abdominal discomfort,  Hypertension, Peripheral Oedema, and Congestive heart failure 
reported with 1 (5.3%) patients each (Table 6.16 & Figure 6.14) 
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Table: 6.16 
Table showing reported ADRs of Gliclazide 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 Nausia/Vomiting 1 5.26 
2 Abdominal discomfort 1 5.26 
3 Headache 2 10.53 
4 Renal impairment 2 10.53 
5 Hypoglycemia 2 10.53 
6 Hypertension 1 5.26 
7 Impaired Hepatic functions 2 10.53 
8 Oedema peripheral 1 5.26 
9 Dyspnoea 1 5.26 
10 pancreatitis 3 15.79 
11 Weight gain 2 10.53 
12 Congestive heart failure 1 5.26 
 
Figure: 6.14 
Figure showing reported ADRs of Gliclazide 
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6.13 REPORTED ADRs OF INSULIN 
 
The Insulin reported the highest AE in the form of Hypoglycemia amongst 5 (14.7%) patients 
whereas the second highest AE was with Fatigue, Weight gain, Headache, Dyspnoea and 
Peripheral Oedema which accounts for 8.8% with 3 patients of each AE. The Nausia, Lactic 
acidosis, Hyponatraemia and Impaired Hepatic functions accounts for 2 patients each which 
contributes to 5.9% each of the AE. Apart from the mentioned AEs minor AEs like 
Dizziness, Hypertension, and Congestive Heart failure were accounting for 3% each with 1 
patient each of the AE. (Table 6.17& Figure 6.15) 
  
Table: 6.17 
Table showing reported ADRs of Insulin 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 Hypoglycemia 5 14.71 
2 Dizziness 1 2.94 
3 Lactic acidosis 2 5.88 
4 Asthenia 2 5.88 
5 Weight gain 3 8.82 
6 Hypertension 1 2.94 
7 Fatigue 3 8.82 
8 Headache 3 8.82 
9 Hypotension 1 2.94 
10 Nausia/Vomiting 2 5.88 
11 Dyspnoea 3 8.82 
12 Congestive heart failure 1 2.94 
13 Hyponatraemia 2 5.88 
14 Impaired hepatic function 2 5.88 
15 Oedema peripheral 3 8.82 
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Figure: 6.15 
Figure showing reported ADRs of Insulin 
 
 
 
 
 
6.14 REPORTED ADRs OF PIOGLITAZONE 
 
In the Pioglitazone treated patients the highest number of AEs reported were Weight gain, 
Impaired Hepatic functions, Hypglycemia and Pancreatitis with 2 patients each which 
contributes to 13.3% of AEs. Minor AEs like, nausea, Abdominal discomfort, Vision 
problems and Oedema contributes 6.7% each with 1 patient each from the assessment group.  
(Table 6.18 & Figure 6.16) 
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Table: 6.18 
Table showing reported ADRs of Pioglitazone 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 Nausia/Vomiting 1 6.67 
2 Abdominal discomfort 1 6.67 
3 Headache 1 6.67 
4 Renal impairment 1 6.67 
5 Hypoglycemia 2 13.33 
6 Congestive heart failure 1 6.67 
7 Impaired Hepatic functions 2 13.33 
8 Oedema peripheral 1 6.67 
9 Vision problems 1 6.67 
10 pancreatitis 2 13.33 
11 Weight gain 2 13.33 
 
Figure: 6.16 
Figure showing reported ADRs of Pioglitazone 
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6.15 REPORTED ADRS OF SITAGLIPTIN 
Pancreatitis and Impaired Hepatic functions were reported as major AE of Sitagliptin 
treatment which contributes 25% with 2 patients of each AE. Minor AEs like Headache, 
Renal impairment, Hypoglycemia and Erythemia accounts for 12.5% each with 1 patient of 
each AE from the assessment group was reported.  (Table 6.19 & Figure 6.17)  
Table: 6.19 
Table showing the reported ADRs of Sitagliptin 
S.No. Suspected major ADRs Number of ADRs Percentage 
1 pancreatitis 2 25.0 
2 Headache 1 12.5 
3 Renal impairment 1 12.5 
4 Hypoglycemia 1 12.5 
5 Impaired Hepatic functions 2 25.0 
6 Rash/Erythemia 1 12.5 
 
Figure: 6.17 
Figure showing reported ADRs of Sitagliptin
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6.16 SIGNIFICANCE OF CAUSALITY ASSESSMENT  
With a view to observe the level of significance a test was done known as “Kappa test for 
agreement”. These observations suggest that a significant agreement between New Algorithm 
and Naranjo’s Scales was found along with the Kappa value is 0.702 i.e. 70.2% (Table 6.20.1 
& 6.20.2).  
 
Table: 6.20.1 
A Significant agreement between New Algorithm & Naranjo’s 
New 
Algorithm 
Naranjo’s causality 
Total 
Possible Definite Probable Unlikely 
Possible 5 40 3 0 48 
Definite 1 10 4 0 15 
Probable 2 6 28 0 36 
Unlikely 1 0 2 2 5 
Total 9 56 37 2 104 
 
 
Table: 6.20.2 
Kappa test for agreement 
Measure of 
Kappa 
Value 
Asymp std error 
(a) 
Approx T (b) Approx .(sig) 
0.702 0.0576 5.834 0.00 
(a) Not assuming the null hypothesis 
(b) Using the asymptotic standard error assuming the null hypothesis 
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6.17 H IE R A R C H I C A L C L U S T E R   A N A L Y S I S 
 
The Hierarchical cluster analysis were showing that there was no significance of Age, sex, 
body weight  with ADRs  this observations suggest that the ADRs were not dependent of 
Age, sex and body weight of the patients  
 
6.18. DISCUSSION 
 
India has more than half a million qualified Doctors and 15,000 hospitals having bed 
strength of 6.24,000. It is the fourth largest producer of pharmaceuticals in the world. It is 
emerging as an important Clinical trial hub in the world. Many new drugs are being 
introduced in our country. Therefore, there is a need for a vibrant pharmacovigilance system 
in the country to protect the population from the potential harm that may be caused by some 
of these new drugs (Ghosh, et al., 2011). The US FDA has released a safety warning against 
rosiglitazone, a drug approved to treat Type 2 diabetes mellitus. An analysis by prominent 
cardiologist Steven Nissen, published his clinical trial results related to adverse drug 
reactions of rosiglitazone. It suggests that 43% of the population (from the trial subjects) have 
a chance of suffering a heart attack (Nissen and Wolski., 2007).  
During 1999, the popular pain killer rofecoxib (Vioxx) was launched by Merck had 
serious adverse effects on cardiovascular system such as heart attack and stroke. This was 
testified by FDA whistle blower and finally the pain killer rofecoxib was pulled out of the 
market by Merck during 2004. In this case also the same scientist Nissen has raised early 
warning of heart attack and stroke by his research.  
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These case studies, further testifies the urgent need of a pharmacovigilance program 
in India for even Generic drugs which are already marketed elsewhere in the world (Biswas 
and Biswas, 2007). 
Pharmacovigilance has not picked up well in India and the subject is in its infancy. 
India rates below 1% in pharmacovigilance as against the world rate of 5%. This is due to 
ignorance of the subject and also lack of training. The office of the Drugs Controller General 
of India has attempted to implement a pharmacovigilance program in India without much 
success. A regulation is required to implement the system of reporting adverse events of 
drugs introduced in the Indian market by pharmaceutical companies. The Government has to 
play an important role in ensuring the availability of safe medicines to public (Ghosh et al., 
2011).  
The mind set of all including the bureaucrats and politicians and healthcare 
professionals need to be changed. The politicians and bureaucrats need only to support with 
full powers to the Drugs Controller General of India and the professionals. With the help of 
all stakeholders, let us pledge to make this happen in India and build a world-class 
pharmacovigilance system and safe more life from new drug toxicity tragedy.  
Pharmacovigilance is a demanding science offering great opportunities for reducing 
harm to patients and costs to healthcare systems. From small beginnings, with the right 
knowledge and skills, pharmacovigilance can make an important contribution to the health of 
the nation 
Different classification of anti-diabetic drugs involved in various adverse reactions were 
assessed during this study. The outcome of the study indicated that biguanides (metformin) 
has been reported with majority of diarrhoea (abdominal upset) followed by other minor 
adverse drug reactions. From the sulfonyl urea class we have assessed gliclazide and found 
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that the major adverse drug reaction was pancreatitis. This could be due to increased stress on 
the pancreas with limited beta cell to secret insulin for the body requirement. The peptide 
hormone group insulin was reported with majority with hypoglycaemia and often leads to 
coma stage. However during our interaction, we did not come across any coma patients. The 
other major adverse reaction for insulin reported is carcinoma, during our study period we did 
not come across any carcinoma patients. Our assessment to insulin shows hypoglycaemia as 
major reported adverse drug reaction. Thiozolidinethione classification drug pioglitazone was 
assessed for adverse drug reaction and hepatic impairment was reported as main adverse drug 
reaction. Finally the DPP-4 inhibitor classification Sitagliptin reported with pancreatitis as 
major adverse drug reaction.  
Majority of adverse drug reactions observed from the classification of drugs were between 
mild to moderate.  
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7. CONCLUSION 
All these adverse drug reports published and available in the public domain has given 
the inspiration of selecting the current study involving pharmacovigilance in diabetes mellitus 
treatment. This study also indicated the types of adverse reactions occurred during the 
diabetes mellitus treatment. In this present study I have selected four different grout of 
medicines available for diabetes treatment e.g, first line therapy for type-1 diabetes is insulin 
and first line therapy for type 2 diabetes is metformin, followed by pioglitazone and DPP-4 
inhibitor sitagliptin. These drugs have various kind of adverse reactions across age and body 
weight distribution. From our finding it is evident that female gender is more affected by 
these adverse reactions than male genders. This could be due to hormonal changes occurs in 
the female compared to male. Further, the new algorithm followed in this study was well in 
agreement with the conventional analysis by Naranjo’s casualty analysis method. This was 
further confirmed using kappa test using statistical analysis.     
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